(Q40182275)

English

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

scientific article published on 18 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

Alexander M Menzies

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Richard F. Kefford

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Georgina V. Long

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

M T Ashworth

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S Swann

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

K Flaherty

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Weber

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J R Infante

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

K B Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R Gonzalez

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

O Hamid

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

L Schuchter

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J A Sosman

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S Little

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

P Sun

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

G Aktan

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

D Ouellet

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

F Jin

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

18 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

415-421

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU529

21 January 2018

Identifiers

10.1093/ANNONC/MDU529

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411413%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40182275&oldid=1888443242"